Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine. Neutralizing antibody responses 1 month after ...

Gastrointestinal tumors remain a global health challenge, with high incidence and mortality. Among them, colorectal cancer (CRC) carries the heaviest burden and serves as a key model for how the gut ...

A new review looks at the challenges of testing for Clostridioides (Clostridium) difficile infection (CDI) and recommendations for newer diagnostic tests. Accurate diagnosis of CDI is critical for ...

A study funded by the National Institutes of Health found that Glucosyltransferase domain is a possible molecular target for therapeutic interventions for Clostridioides difficile infection.

Scientists have made a breakthrough in the hunt for a new vaccine for killer hospital bug Clostridioides difficile (C. diff). Scientists have made a breakthrough in the hunt for a new vaccine for ...

Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile—commonly known as C. diff—are a serious and persistent problem for patients and hospitals ...

Scientists at Emory University School of Medicine have identified a central regulator of toxin production in the bacterium C. difficile, the most common cause of healthcare-associated infections in ...

A University of California, Irvine-led study suggests that the glucosyltransferase domain (GTD) is an ideal molecular target for therapeutic interventions for Clostridioides difficile infection (CDI).

EAST SYRACUSE, N.Y. (WSYR-TV) — The Upstate Institute for Global Health is looking for over 1,000 Central New Yorkers to participate in its largest clinical trial, testing a possible vaccine to ...

Scientists have made a breakthrough in the hunt for a new vaccine for killer hospital bug Clostridioides difficile (C. diff). University of Exeter researchers first identified a gene in C. diff ...